TNFSF11 and Hypocalcemia: Hence the decreased calcium level could probably be explained that denosumab inhibits bone resorption by binding to RANKL, thus inhibiting the mobilization of stored calcium and phosphate, leading to less bone calcium and phosphorus release, eventually resulting in hypocalcemia and hypophosphatemia (Dempster et al., 2012).